Long COVID és ME/CFS: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• IL-6 1
• ACE2 0
• mTOR 0
• NLRP3 0
• PI3K 0
• TNF 0
• AMPK 0
• CD38 1
• GLP-1 0
• IL-15 1
• JAK 0
• MMP-9 0
• AKT 0
• APOE 0
• AQP4 0
• BDNF 0
• CD19 1
• CD40 0
• HIF-1 0
• HSP90 0
• IL-1 0
• IL-17 0
• NMDA 0
• PD-1 1
• SGLT2 0
• TFEB 0
• TP53 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Navigating Work-Nonwork Boundaries in Hybrid Work: Exploring Career Trajectories and Intersectional Challenges for Professional Women (HYBWORKEXP)

  Ism Vadybos Ir Ekonomikos Universitetas Uab· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Nutrition AI for Well-Being and Social Inclusion (NutriWell)

  Innova Living· Sofia, Bulgária· EU contribution 499 629 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Biological evidence and mechanism-based disease classification for the improved diagnosis, prognosis and treatment of ME/CFS (DISCOVER-ME)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 7 588 595 EUR· until 2030. jún.· 12 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Kefiran: Harnessing Exopolysaccharide bioActivities beneficiaL To Health (KHEALTH)

  Teagasc - Agriculture and Food Development Authority· Carlow, Írország· EU contribution 252 729 EUR· until 2028. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Housing, Inequality, and Price-Setting: Theory, Evidence, and Ramifications for the Macroeconomy (HIPSTERMacro)

  Stockholms Universitet· Stockholm, Svédország· EU contribution 1 504 353 EUR· until 2030. szept.

  The disease is named only in the funder's project summary, not in the title.

5 of 17 running projects, newest first. Listed amounts together: 68,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

  NCT07388550· National Institute of Neurological Disorders and Stroke (NINDS)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 7
• Organoids 1
• Mendelian Randomization Analysis 4
• Gene Expression Profiling 20
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 6
• Proteomics 40
• Metabolomics 20
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 49
• Machine Learning 32
• Deep Learning 5
• Cohort Studies 92
• Genome-Wide Association Study 11

• Identification of SGK1 as a candidate regulator associated with myeloid cell senescence in ME/CFS: An integrative transcriptomic and experimental study.

  PLoS One, 2026. okt.

• Is Cellular Senescence a Biological Feature of Long COVID? A Transcriptomic Analysis Across Comparative Postacute Sequelae Phenotypes.

  J Infect Dis, 2026. okt.

• SpxA1 and SpxA2 function as a stoichiometry-dependent regulatory rheostat governing virulence gene expression in group A Streptococcus.

  mBio, 2026. aug.

• Circulating extracellular vesicles-microRNAs as potential biomarkers for the identification of ME/CFS: differentiating fatigue-related conditions.

  J Transl Med, 2026. júl.

• Convergent genetic and structural parameters of cardiovascular disease related insights of post-acute COVID-19.

  Biochem Biophys Res Commun, 2026. júl.

• Integrative hematological and transcriptomic analysis reveals monocyte alterations and molecular signatures of inflammatory-coagulation crosstalk in long COVID.

  Comput Biol Chem, 2026. júl.

• Integrated miRNAome-transcriptome analyses identify an immuno-hematopoietic subcluster in patients with long COVID.

  J Allergy Clin Immunol, 2026. jún.

• Pilot longitudinal integrated transcriptomic-metabolomic study reveals immune and metabolic signatures in non-hospitalized healthcare workers with long COVID.

  Front Cell Infect Microbiol, 2026. jún.

• Immune dysregulation in prolonged Long-COVID: lymphocytes emerge as key mediators of persistent inflammation, exhaustion and cytotoxicity.

  J Transl Med, 2026. ápr.

• Single-Cell Transcriptomic Analysis of Salivary Epithelial Cells Reveals Large-Scale Dysregulation in Bitter Taste Dysfunction.

  Int J Mol Sci, 2026. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.